The Effect of Antiviral Therapy with Tenofovir on Liver Fibrosis and Liver Function in Patients with Chronic Hepatitis B

Aim of investigation: The aim of the present study was to evaluate the possibility using of indirect liver fibrosis markers for the estimation of fibrosis severity and timely prescribing of antiviral therapy in patients with chronic hepatitis B.Materials and methods: We examined 130 patients with chronic hepatitis B (mean age 41,8±13,5 years, 70% of men) having known liver fibrosis stage based on fibroelastography or liver biopsy. The age of patients, 9 parameters of biochemical blood analysis, complete blood count and coagulogram along with 7 indices calculated on their base were considered. Their prognostic values were estimated by means of ROC analysis.Results: According to increase of liver fibrosis stage albumin, prothrombin index, platelet count, cholesterol reduce and aspartate aminotransferase, international normalized ratio, gamma-glutamyl transpeptidase, alanine aminotransferase, alkaline phosphatase levels rise (p<0,01). All of the laboratory parameters and indices were significantly different (p<0,01) in patients with minimal (F0–F1) and advanced (F2–F4) fibrosis. For patients with chronic hepatitis B the most significant predictors of advanced liver fibrosis (F2–F4) were: GUCI and King’s score indices as well as eLIFT scale. Index GUCI had the best diagnostic performance (area under the receiver operating characteristic curve 0,866) with 89,5% sensitivity and 78,0% specificity at cut off ≥0,7/ Conclusion: The assessment of indirect liver fibrosis markers in patients with chronic hepatitis B can be easily performed at any stage of medical care; they are quite informative and can be used for the estimation of fibrosis severity and timely conducting antiviral therapy.

Download Full-text

Clinical features of chronic B hepatitis in children depending on treatment response

Russian Medical Inquiry ◽

10.32364/2587-6821-2020-4-11-682-686 ◽

2020 ◽

Vol 4 (11) ◽

pp. 682-686

Author(s):

O.V. Churbakovа ◽

◽

V.G. Akimkin ◽

D.V. Pechkurov ◽

◽

...

Keyword(s):

Chronic Hepatitis ◽

Liver Fibrosis ◽

Hepatitis B ◽

Antiviral Therapy ◽

Treatment Response ◽

Chronic Hepatitis B ◽

Clinical Features ◽

Sustained Virologic Response ◽

Antiviral Treatment ◽

Virologic Response

Background: chronic hepatitis is a common infection in all age groups. The optimization of therapeutic approaches is an important medical social and national economic issue. Aim: to describe the clinical and laboratory features of chronic hepatitis B (CHB) in children depending on the efficacy of antiviral therapy. Patients and Methods: 31 children aged 3–17 years with НBeAg-negative CHB who were treated in the Children’s Infectious Department of N.A. Semashko Samara City Clinical Hospital No. 2 and then monitored in a children’s hepatological center were enrolled. These children received no prior antiviral treatment. T he efficacy of antivirals and CHB outcomes over a 6-year perio d were evaluated. Results: the changes in clinical and biochemical parameters in children with CHB depending on treatment response were analyzed. All children were prescribed with antiviral therapy according to Diagnosis and Treatment Protocol for Hepatitis B and C (2010). In 14 (45.2%) children who received antiviral therapy, sustained virologic response was achieved after 48 weeks. In these children, no cases of liver fibrosis were reported over a 6-year period. Meanwhile, in the group without sustained virologic response after antiviral therapy (n=17), 1 patient was diagnosed with liver fibrosis stage 1 and 2 patients were diagnosed with Child class A cirrhosis. Conclusion: despite countrywide HBV vaccination, the incidence of CHB is still high thus requiring the development of novel diagnostic and therapeutic strategies. KEYWORDS: chronic hepatitis B, children, differential therapy, viral host response, prognosis. FOR CITATION: Churbakovа O.V., Akimkin V.G., Pechkurov D.V. Clinical features of chronic B hepatitis in children depending on treatment response. Russian Medical Inquiry. 2020;4(11):682–686. DOI: 10.32364/2587-6821-2020-4-11-682-686.

Download Full-text

RELATIONSHIP OF SERUM ADIPONECTIN AND RESISTIN LEVELS WITH THE SEVERITY OF LIVER FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS B

Journal of Medical Biochemistry ◽

10.5937/jomb0-33793 ◽

2021 ◽

Author(s):

Nerma Čustović ◽

Senija Rašić

Keyword(s):

Chronic Hepatitis ◽

Liver Fibrosis ◽

Hepatitis B ◽

Antiviral Therapy ◽

Chronic Hepatitis B ◽

Serum Adiponectin ◽

Control Group ◽

Cross Sectional ◽

Significant Difference ◽

Apri Score

Background: Recent research has closely linked adipocytokines to progression of liver inflammation and fibrosis in patients with non-alcoholic liver disease. The aim of this study was to determine the relationship ofserum adiponectin and resistin levels with the severity of liver fibrosis in patients with chronic hepatitis B (CHB), depending on the duration of antiviral therapy. Methods: The cross-sectional studyincluded75 patients with CHB divided into two groups: T1 group(on antiviral therapy for up to 2 years) and T2 group (on antiviral therapy over 2 years). Control group consisted of 40 healthy persons. Serum concentrations of adiponectin and resistin were estimated with ELISA method, while degree of liver fibrosis was determined using FIB-4and APRIscore. Results:The higher values of serum resistin concentration were verified in patients with CHBcompared to healthy controls. The mean level of serum resistin concentration was significantly higher in group of patients with higher FIB-4 score (9.12±3.39 vs. 5.58±3.36 ng/mL, p = 0.001), as well as APRI score (17.45 ± 3.96ng/mL vs.4.82 ± 1.11 ng/mL, p = 0.001). Positive correlation was found between serum resistin levels and degree of liver fibrosis (p < 0.001). There was no significant difference between mean serum adiponectin levels according to the values of FIB-4 and APRI scores. Conclusions:Serum resistin concentration could be a potential noninvasive biomarker of the severity of liver fibrosis in patients with chronic hepatitis B on antiviral therapy.

Download Full-text